Smart Clot is a new tool for measuring the haemorrhagic and thrombogenic potential “ex vivo” of patients affected by cardiovascular diseases and/or thrombotic-haemorrhagic disorders, and for monitoring the effects of anticoagulation and antiplatelet drug therapy.
The test is highly innovative insofar as it simultaneously measures platelet activation and the deposit of fibrin under controlled flux conditions (venous and arterial) using just one small whole blood sample.
The Smart Clot test can be used by medical specialists (anaesthetists, haematologists, cardiologists, heart surgeons, etc.) to both accurately evaluate the disorder and to monitor the effects of antiplatelet and/or anticoagulation therapy.
The Smart Clot test is set to become the “must have” device for haematologists and cardiologists and for any clinical situation or thrombotic disorder that requires the administration of antiplatelet or anticoagulant drugs such as cardiovascular diseases, neurological strokes, thrombosis, pulmonary embolisms, diabetes, surgery of any kind, etc.
Total raised: $1.171316M
Founded date: 2005
Investors 1
| Date | Name | Website |
| - | Italian An... | italianang... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 08.05.2012 | - | $1.171316M | - | finsmes.co... |
Mentions in press and media 1
| Date | Title | Description | Source |
| 08.05.2012 | SediciDodici Raises €900K in Angel Funding | SediciDodici, a Pordenone Technology Park, Italy-based medtech startup, has raised €900k in first fu... | finsmes.co... |